Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers

References

• Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation1(1), 14 (2004).
   PubMed Web of Science ®Google Scholar
• Harry GJ, Kraft AD. Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment. Expert Opin. Drug Metab. Toxicol.4(10), 1265–1277 (2008).
   PubMed Web of Science ®Google Scholar
• Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol.119(1), 89–105 (2010).
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol.27, 119–145 (2009).
   PubMed Web of Science ®Google Scholar
• Pivneva TA. Microglia in normal condition and pathology. Fiziol. Zh.54(5), 81–89 (2008).
   Google Scholar
• Lynch MA. The multifaceted profile of activated microglia. Mol. Neurobiol.40(2), 139–156 (2009).
   PubMed Web of Science ®Google Scholar
• Seth P, Koul N. Astrocyte, the star avatar: redefined. J. Biosci.33(3), 405–421 (2008).
   PubMed Web of Science ®Google Scholar
• Wang DD, Bordey A. The astrocyte odyssey. Prog. Neurobiol.86(4), 342–367 (2008).
   PubMed Web of Science ®Google Scholar
• Araque A, Perea G. Glial modulation of synaptic transmission in culture. Glia47(3), 241–248 (2004).
   PubMed Web of Science ®Google Scholar
• Norton WT, Aquino DA, Hozumi I, Chiu FC, Brosnan CF. Quantitative aspects of reactive gliosis: a review. Neurochem. Res.17(9), 877–885 (1992).
   PubMed Web of Science ®Google Scholar
• Kim SU, de Vellis J. Microglia in health and disease. J. Neurosci. Res.81(3), 302–313 (2005).
   PubMed Web of Science ®Google Scholar
• Walter L, Neumann H. Role of microglia in neuronal degeneration and regeneration. Semin. Immunopathol.31(4), 513–525.
   PubMedGoogle Scholar
• Sanders P, De Keyser J. Janus faces of microglia in multiple sclerosis. Brain Res. Rev.54(2), 274–285 (2007).
   PubMedGoogle Scholar
• Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J. Biochem. (Tokyo)130(2), 169–175 (2001).
   PubMed Web of Science ®Google Scholar
• Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther.304(1), 1–7 (2003).
   PubMed Web of Science ®Google Scholar
• Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun. Rev.3(4), 251–260 (2004).
   PubMed Web of Science ®Google Scholar
• Olson EE, McKeon RJ. Characterization of cellular and neurological damage following unilateral hypoxia/ischemia. J. Neurol. Sci.227(1), 7–19 (2004).
   PubMed Web of Science ®Google Scholar
• Morioka T, Kalehua AN, Streit WJ. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J. Comp. Neurol.327(1), 123–132 (1993).
   PubMed Web of Science ®Google Scholar
• Inoue K, Tsuda M. Microglia and neuropathic pain. Glia57(14), 1469–1479 (2009).
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging21(3), 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol. Sci.29(12), 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med.10(10), 1055–1063 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol.82, 235–246 (2007).
   PubMed Web of Science ®Google Scholar
• Kim YS, Joh TH. Microglia major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med.38(4), 333–347 (2006).
   PubMed Web of Science ®Google Scholar
• Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson’s disease. Prog. Neurobiol.89(3), 277–287 (2009).
   PubMed Web of Science ®Google Scholar
• Villoslada P, Steinman L, Baranzini SE. Systems biology and its application to the understanding of neurological diseases. Ann. Neurol.65(2), 124–139 (2009).
   PubMed Web of Science ®Google Scholar
• Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature461(7266), 908–915 (2009).
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Farez MF, Weiner HL. Systems biology approaches for the study of multiple sclerosis. J. Cell Mol. Med.12(4), 1087–1093 (2008).
   PubMed Web of Science ®Google Scholar
• Vodovotz Y, Csete M, Bartels J, Chang S, An G. Translational systems biology of inflammation. PLoS Comput. Biol.4(4), e1000014 (2008).
   PubMed Web of Science ®Google Scholar
• Grant SG. Systems biology in neuroscience: bridging genes to cognition. Curr. Opin. Neurobiol.13(5), 577–582 (2003).
   PubMedGoogle Scholar
• Hwang D, Lee IY, Yoo H et al. A systems approach to prion disease. Mol. Syst. Biol.5, 252 (2009).
   PubMed Web of Science ®Google Scholar
• Kandpal R, Saviola B, Felton J. The era of ‘omics unlimited. Biotechniques46(5), 351–352, 354–355 (2009).
   PubMed Web of Science ®Google Scholar
• Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol.15(1), 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science295(5560), 1662–1664 (2002).
   PubMed Web of Science ®Google Scholar
• Kirschner MW. The meaning of systems biology. Cell121(4), 503–504 (2005).
   PubMedGoogle Scholar
• Aderem A. Systems biology: its practice and challenges. Cell121(4), 511–513 (2005).
   PubMed Web of Science ®Google Scholar
• Liu ET. Systems biology, integrative biology, predictive biology. Cell121(4), 505–506 (2005).
   PubMed Web of Science ®Google Scholar
• Petranovic D, Nielsen J. Can yeast systems biology contribute to the understanding of human disease? Trends Biotechnol.26(11), 584–590 (2008).
   PubMedGoogle Scholar
• Hathout Y. Approaches to the study of the cell secretome. Expert Rev. Proteomics4(2), 239–248 (2007).
   PubMed Web of Science ®Google Scholar
• Weston AD, Hood L. Systems biology, proteomics and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res.3(2), 179–196 (2004).
   PubMed Web of Science ®Google Scholar
• Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M. Interrelating different types of genomic data, from proteome to secretome: ‘oming in on function. Genome Res.11(9), 1463–1468 (2001).
   PubMed Web of Science ®Google Scholar
• Grimmond SM, Miranda KC, Yuan Z et al. The mouse secretome: functional classification of the proteins secreted into the extracellular environment. Genome Res.13(6B), 1350–1359 (2003).
   PubMed Web of Science ®Google Scholar
• Thouvenot E, Lafon-Cazal M, Demettre E, Jouin P, Bockaert J, Marin P. The proteomic analysis of mouse choroid plexus secretome reveals a high protein secretion capacity of choroidal epithelial cells. Proteomics6(22), 5941–5952 (2006).
   PubMed Web of Science ®Google Scholar
• Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG. Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene25(58), 7650–7661 (2006).
   PubMed Web of Science ®Google Scholar
• Pellitteri-Hahn MC, Warren MC, Didier DN et al. Improved mass spectrometric proteomic profiling of the secretome of rat vascular endothelial cells. J. Proteome Res.5(10), 2861–2864 (2006).
   PubMed Web of Science ®Google Scholar
• Zvonic S, Lefevre M, Kilroy G et al. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol. Cell Proteomics6(1), 18–28 (2007).
   PubMed Web of Science ®Google Scholar
• Dupont A, Corseaux D, Dekeyzer O et al. The proteome and secretome of human arterial smooth muscle cells. Proteomics5(2), 585–596 (2005).
   PubMed Web of Science ®Google Scholar
• Dupont A, Tokarski C, Dekeyzer O et al. Two-dimensional maps and databases of the human macrophage proteome and secretome. Proteomics4(6), 1761–1778 (2004).
   PubMed Web of Science ®Google Scholar
• Lafon-Cazal M, Adjali O, Galeotti N et al. Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J. Biol. Chem.278(27), 24438–24448 (2003).
   PubMed Web of Science ®Google Scholar
• Delcourt N, Jouin P, Poncet J et al. Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes. Mol. Cell Proteomics4(8), 1085–1094 (2005).
   PubMedGoogle Scholar
• Wu HY, Chang YH, Chang YC, Liao PC. Proteomics analysis of nasopharyngeal carcinoma cell secretome using a hollow fiber culture system and mass spectrometry. J. Proteome Res.8(1), 380–389 (2009).
   PubMed Web of Science ®Google Scholar
• Dowell JA, Johnson JA, Li L. Identification of astrocyte secreted proteins with a combination of shotgun proteomics and bioinformatics. J. Proteome Res.8(8), 4135–4143 (2009).
   PubMed Web of Science ®Google Scholar
• Keene SD, Greco TM, Parastatidis I et al. Mass spectrometric and computational analysis of cytokine-induced alterations in the astrocyte secretome. Proteomics9(3), 768–782 (2009).
   PubMedGoogle Scholar
• Kim S, Ock J, Kim AK et al. Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J. Neurochem.103(6), 2640–2650 (2007).
   PubMedGoogle Scholar
• Liu J, Hong Z, Ding J, Liu J, Zhang J, Chen S. Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies. J. Proteome Res.7(5), 2033–2049 (2008).
   PubMed Web of Science ®Google Scholar
• Mohri I, Taniike M, Taniguchi H et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J. Neurosci.26(16), 4383–4393 (2006).
   PubMed Web of Science ®Google Scholar
• Hansson E, Ronnback L. Glial neuronal signaling in the central nervous system. FASEB J.17(3), 341–348 (2003).
   PubMed Web of Science ®Google Scholar
• Biber K, Vinet J, Boddeke HW. Neuron-microglia signaling: chemokines as versatile messengers. J. Neuroimmunol.198(1–2), 69–74 (2008).
   PubMed Web of Science ®Google Scholar
• Wang T, Gong N, Liu J et al. HIV-1-infected astrocytes and the microglial proteome. J. Neuroimmune Pharmacol.3(3), 173–186 (2008).
   PubMed Web of Science ®Google Scholar
• Rohl C, Armbrust E, Kolbe K et al. Activated microglia modulate astroglial enzymes involved in oxidative and inflammatory stress and increase the resistance of astrocytes to oxidative stress in vitro. Glia56(10), 1114–1126 (2008).
   PubMedGoogle Scholar
• Tannu NS, Hemby SE. Methods for proteomics in neuroscience. Prog. Brain Res.158, 41–82 (2006).
   PubMed Web of Science ®Google Scholar
• Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics4(1), 51–65 (2007).
   PubMed Web of Science ®Google Scholar
• Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief. Funct. Genomic Proteomic4(1), 16–26 (2005).
   PubMedGoogle Scholar
• Findeisen P, Neumaier M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev. Proteomics6(5), 457–459 (2009).
   PubMed Web of Science ®Google Scholar
• Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med.6, 52 (2008).
   PubMed Web of Science ®Google Scholar
• Zwickl H, Traxler E, Staettner S et al. A novel technique to specifically analyze the secretome of cells and tissues. Electrophoresis26(14), 2779–2785 (2005).
   PubMedGoogle Scholar
• Enose Y, Destache CJ, Mack AL et al. Proteomic fingerprints distinguish microglia bone marrow, and spleen macrophage populations. Glia51(3), 161–172 (2005).
   PubMedGoogle Scholar
• Potolicchio I, Carven GJ, Xu X et al. Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J. Immunol.175(4), 2237–2243 (2005).
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated α-synuclein microglia regulation by CD4+CD25+ T cells. J. Proteome Res.8(7), 3497–3511 (2009).
   PubMed Web of Science ®Google Scholar
• Bernhart E, Kollroser M, Rechberger G et al. Lysophosphatidic acid receptor activation affects the C13NJ microglial cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics10(1), 141–158 (2010).
   PubMedGoogle Scholar
• Egnaczyk GF, Pomonis JD, Schmidt JA et al. Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics3(5), 689–698 (2003).
   PubMed Web of Science ®Google Scholar
• Yang JW, Suder P, Silberring J, Lubec G. Proteome analysis of mouse primary astrocytes. Neurochem. Int.47(3), 159–172 (2005).
   PubMedGoogle Scholar
• Hauck SM, Suppmann S, Ueffing M. Proteomic profiling of primary retinal Muller glial cells reveals a shift in expression patterns upon adaptation to in vitro conditions. Glia44(3), 251–263 (2003).
   PubMed Web of Science ®Google Scholar
• Pocernich CB, Boyd-Kimball D, Poon HF et al. Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res. Mol. Brain Res.133(2), 307–316 (2005).
   PubMedGoogle Scholar
• Moore NH, Costa LG, Shaffer SA, Goodlett DR, Guizzetti M. Shotgun proteomics implicates extracellular matrix proteins and protease systems in neuronal development induced by astrocyte cholinergic stimulation. J. Neurochem.108(4), 891–908 (2009).
   PubMed Web of Science ®Google Scholar
• Thouvenot E, Urbach S, Dantec C et al. Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. J. Proteome Res.7(10), 4409–4421 (2008).
   PubMedGoogle Scholar
• Bachoo RM, Kim RS, Ligon KL et al. Molecular diversity of astrocytes with implications for neurological disorders. Proc. Natl Acad. Sci. USA101(22), 8384–8389 (2004).
   PubMedGoogle Scholar
• Cahoy JD, Emery B, Kaushal A et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci.28(1), 264–278 (2008).
   PubMed Web of Science ®Google Scholar
• Gabelle A, Roche S, Lehmann S. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders]. Rev. Neurol. (Paris)165(3), 213–222 (2009).
   PubMedGoogle Scholar
• Maurer MH. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom. Rev.29(1), 17–28 (2010).
   PubMed Web of Science ®Google Scholar
• Westman-Brinkmalm A, Ruetschi U, Portelius E et al. Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases. Front. Biosci.14, 1793–1806 (2009).
   Google Scholar
• Zougman A, Pilch B, Podtelejnikov A et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res.7(1), 386–399 (2008).
   PubMed Web of Science ®Google Scholar
• Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med.348(14), 1356–1364 (2003).
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Petzold A, Bennett JL et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology73(22), 1914–1922 (2009).
   PubMed Web of Science ®Google Scholar
• Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn.8(4), 479–494 (2008).
   PubMed Web of Science ®Google Scholar
• Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics2(1), 57–70 (2005).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech. Ageing Dev.127(2), 133–137 (2006).
   PubMedGoogle Scholar
• Ekegren T, Hanrieder J, Bergquist J. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. J. Mass Spectrom.43(5), 559–571 (2008).
   PubMed Web of Science ®Google Scholar
• Pan S, Zhu D, Quinn JF et al. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics7(3), 469–473 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis.8(4), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer’s disease. Biochim. Biophys. Acta1782(10), 549–558 (2008).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol.65(4), 403–413 (2009).
   PubMed Web of Science ®Google Scholar
• Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res.1265, 158–170 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis.7(2), 125–133; discussion 173–180 (2005).
   PubMed Web of Science ®Google Scholar
• Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer’s disease and normal controls. J. Alzheimers Dis.18(2), 331–337 (2009).
   PubMed Web of Science ®Google Scholar
• Jesse S, Steinacker P, Cepek L et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer’s disease and Creutzfeldt-Jakob disease. J. Alzheimers Dis.17(3), 541–551 (2009).
   PubMedGoogle Scholar
• Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol.5(10), 561–570 (2009).
   PubMed Web of Science ®Google Scholar
• Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis.9(3), 293–348 (2006).
   PubMed Web of Science ®Google Scholar
• Constantinescu R, Zetterberg H, Holmberg B, Rosengren L. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat. Disord.15(3), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Mitchell RM, Freeman WM, Randazzo WT et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology72(1), 14–19 (2009).
   PubMed Web of Science ®Google Scholar
• Brechlin P, Jahn O, Steinacker P et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics8(20), 4357–4366 (2008).
   PubMed Web of Science ®Google Scholar
• Bayes A, Grant SG. Neuroproteomics: understanding the molecular organization and complexity of the brain. Nat. Rev. Neurosci.10(9), 635–646 (2009).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J. Neural Transm.116(9), 1163–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Choi C, Jeong JH, Jang JS et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer’s disease by color-coded bead technology. J. Clin. Neurol.4(2), 84–88 (2008).
   PubMedGoogle Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56(9), 1143–1153 (2001).
   PubMed Web of Science ®Google Scholar
• Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer’s disease and other forms of dementia: clinical needs, limitations and future aspects. Exp. Gerontol.45(1), 5–14 (2010).
   PubMedGoogle Scholar
• Kunz GM Jr, Chan DW. The use of laser capture microscopy in proteomics research – a review. Dis. Markers20(3), 155–160 (2004).
   PubMedGoogle Scholar
• Ye X, Blonder J, Veenstra TD. Targeted proteomics for validation of biomarkers in clinical samples. Brief Funct. Genomic Proteomic8(2), 126–135 (2009).
   PubMedGoogle Scholar
• Yocum AK, Chinnaiyan AM. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief. Funct. Genomic Proteomic8(2), 145–157 (2009).
   PubMedGoogle Scholar
• Pan S, Aebersold R, Chen R et al. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res.8(2), 787–797 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics5(4), 573–588 (2006).
   PubMed Web of Science ®Google Scholar
• Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell138(4), 795–806 (2009).
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ et al. Identification of potential CSF biomarkers in ALS. Neurology66(8), 1218–1222 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor KC, Roy SM, Becker CH, Hafler DA, Kantor AB. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis. Markers22(4), 213–225 (2006).
   PubMed Web of Science ®Google Scholar
• Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol. Neurobiol.29(2), 203–210 (2009).
   PubMed Web of Science ®Google Scholar